These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 35176144)

  • 21. A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of ad5/3-Δ24 in advance of a phase I clinical trial in ovarian cancer patients.
    Kim KH; Ryan MJ; Estep JE; Miniard BM; Rudge TL; Peggins JO; Broadt TL; Wang M; Preuss MA; Siegal GP; Hemminki A; Harris RD; Aurigemma R; Curiel DT; Alvarez RD
    Hum Gene Ther; 2011 Jul; 22(7):821-8. PubMed ID: 21171861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers.
    Chang J; Zhao X; Wu X; Guo Y; Guo H; Cao J; Guo Y; Lou D; Yu D; Li J
    Cancer Biol Ther; 2009 Apr; 8(8):676-82. PubMed ID: 19242097
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial.
    Nassiri F; Patil V; Yefet LS; Singh O; Liu J; Dang RMA; Yamaguchi TN; Daras M; Cloughesy TF; Colman H; Kumthekar PU; Chen CC; Aiken R; Groves MD; Ong SS; Ramakrishna R; Vogelbaum MA; Khagi S; Kaley T; Melear JM; Peereboom DM; Rodriguez A; Yankelevich M; Nair SG; Puduvalli VK; Aldape K; Gao A; López-Janeiro Á; de Andrea CE; Alonso MM; Boutros P; Robbins J; Mason WP; Sonabend AM; Stupp R; Fueyo J; Gomez-Manzano C; Lang FF; Zadeh G
    Nat Med; 2023 Jun; 29(6):1370-1378. PubMed ID: 37188783
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial.
    Fares J; Ahmed AU; Ulasov IV; Sonabend AM; Miska J; Lee-Chang C; Balyasnikova IV; Chandler JP; Portnow J; Tate MC; Kumthekar P; Lukas RV; Grimm SA; Adams AK; Hébert CD; Strong TV; Amidei C; Arrieta VA; Zannikou M; Horbinski C; Zhang H; Burdett KB; Curiel DT; Sachdev S; Aboody KS; Stupp R; Lesniak MS
    Lancet Oncol; 2021 Aug; 22(8):1103-1114. PubMed ID: 34214495
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oncolytic Adenovirus Expressing Monoclonal Antibody Trastuzumab for Treatment of HER2-Positive Cancer.
    Liikanen I; Tähtinen S; Guse K; Gutmann T; Savola P; Oksanen M; Kanerva A; Hemminki A
    Mol Cancer Ther; 2016 Sep; 15(9):2259-69. PubMed ID: 27458139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNX-2401: an investigational drug for the treatment of recurrent glioblastoma.
    Philbrick B; Adamson DC
    Expert Opin Investig Drugs; 2019 Dec; 28(12):1041-1049. PubMed ID: 31726894
    [No Abstract]   [Full Text] [Related]  

  • 27. Treatment of ovarian cancer with a novel dual targeted conditionally replicative adenovirus (CRAd).
    Rocconi RP; Zhu ZB; Stoff-Khalili M; Rivera AA; Lu B; Wang M; Alvarez RD; Curiel DT; Makhija SK
    Gynecol Oncol; 2007 Apr; 105(1):113-21. PubMed ID: 17173958
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Magnetic Resonance Imaging-Based Assessment of Gadolinium-Conjugated Diethylenetriamine Penta-Acetic Acid Test-Infusion in Detecting Dysfunction of Convection-Enhanced Delivery Catheters.
    van Putten EH; Wembacher-Schröder E; Smits M; Dirven CM
    World Neurosurg; 2016 May; 89():272-9. PubMed ID: 26862025
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients.
    García M; Moreno R; Gil-Martin M; Cascallò M; de Olza MO; Cuadra C; Piulats JM; Navarro V; Domenech M; Alemany R; Salazar R
    Hum Gene Ther; 2019 Mar; 30(3):352-364. PubMed ID: 30234393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol.
    Geletneky K; Huesing J; Rommelaere J; Schlehofer JR; Leuchs B; Dahm M; Krebs O; von Knebel Doeberitz M; Huber B; Hajda J
    BMC Cancer; 2012 Mar; 12():99. PubMed ID: 22436661
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer.
    Raki M; Särkioja M; Desmond RA; Chen DT; Bützow R; Hemminki A; Kanerva A
    Gynecol Oncol; 2008 Jan; 108(1):166-72. PubMed ID: 17950450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer.
    Koski A; Raki M; Nokisalmi P; Liikanen I; Kangasniemi L; Joensuu T; Kanerva A; Pesonen S; Alemany R; Hemminki A
    Mol Ther; 2012 Jan; 20(1):221-9. PubMed ID: 22044933
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Toxicology profiles of a novel p53-armed replication-competent oncolytic adenovirus in rodents, felids, and nonhuman primates.
    Su C; Cao H; Tan S; Huang Y; Jia X; Jiang L; Wang K; Chen Y; Long J; Liu X; Wu M; Wu X; Qian Q
    Toxicol Sci; 2008 Nov; 106(1):242-50. PubMed ID: 18703561
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A hydrogel matrix prolongs persistence and promotes specific localization of an oncolytic adenovirus in a tumor by restricting nonspecific shedding and an antiviral immune response.
    Jung BK; Oh E; Hong J; Lee Y; Park KD; Yun CO
    Biomaterials; 2017 Dec; 147():26-38. PubMed ID: 28923683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delta-24-RGD, an Oncolytic Adenovirus, Increases Survival and Promotes Proinflammatory Immune Landscape Remodeling in Models of AT/RT and CNS-PNET.
    Garcia-Moure M; Gonzalez-Huarriz M; Labiano S; Guruceaga E; Bandres E; Zalacain M; Marrodan L; de Andrea C; Villalba M; Martinez-Velez N; Laspidea V; Puigdelloses M; Gallego Perez-Larraya J; Iñigo-Marco I; Stripecke R; Chan JA; Raabe EH; Kool M; Gomez-Manzano C; Fueyo J; Patiño-García A; Alonso MM
    Clin Cancer Res; 2021 Mar; 27(6):1807-1820. PubMed ID: 33376098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Sequence of Delta24-RGD and TMZ Administration in Malignant Glioma Affects the Role of CD8
    Kleijn A; van den Bossche W; Haefner ES; Belcaid Z; Burghoorn-Maas C; Kloezeman JJ; Pas SD; Leenstra S; Debets R; de Vrij J; Dirven CMF; Lamfers MLM
    Mol Ther Oncolytics; 2017 Jun; 5():11-19. PubMed ID: 28480325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor suppressor in lung cancer-1 (TSLC1) mediated by dual-regulated oncolytic adenovirus exerts specific antitumor actions in a mouse model.
    Lei W; Liu HB; Wang SB; Zhou XM; Zheng SD; Guo KN; Ma BY; Xia YL; Tan WS; Liu XY; Wang YG
    Acta Pharmacol Sin; 2013 Apr; 34(4):531-40. PubMed ID: 23503473
    [TBL] [Abstract][Full Text] [Related]  

  • 38. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.
    Xu HN; Huang WD; Cai Y; Ding M; Gu JF; Wei N; Sun LY; Cao X; Li HG; Zhang KJ; Liu XR; Liu XY
    Mol Cancer; 2011 Nov; 10():133. PubMed ID: 22040050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Delivery of oncolytic adenovirus into the nucleus of tumorigenic cells by tumor microparticles for virotherapy.
    Ran L; Tan X; Li Y; Zhang H; Ma R; Ji T; Dong W; Tong T; Liu Y; Chen D; Yin X; Liang X; Tang K; Ma J; Zhang Y; Cao X; Hu Z; Qin X; Huang B
    Biomaterials; 2016 May; 89():56-66. PubMed ID: 26950165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus.
    Xiao LL; Wu YM; Qian J; Tan Y; Xie GL; Zhang KJ; Wang YG; Jia XY; Liu XY
    Cancer Biol Ther; 2010 Aug; 10(3):242-50. PubMed ID: 20574150
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.